What in vitro models of infection can and cannot do

Pharmacotherapy

Volumn 21, Issue 11 II, 2001, Pages

  White, R L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; COMPARTMENT MODEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS;

EID: 0034754449     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.18.292s.33906     Document Type: Conference Paper

References (108)

1. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model
2. In vitro models for the study of antibiotic activities
3. In vitro model for simultaneous simulation of serum kinetics for two drugs with different half-lives
4. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model
5. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: Studies using an in vitro dynamic model
6. Stenotrophomonas maltophilia: Emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model
7. Historical review of in vitro models
8. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity
9. Pharmacokinetic considerations for the setting of in vitro models
10. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model
11. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics
12. Advantages and disadvantages of an in vitro model with two compartments connected by a dialyser: Results of experiments with ciprofloxacin
13. Effect of the ratio of surface area to volume on the penetration of antibiotics into extravascular spaces in an in vitro model
14. Comparison study of the kinetics of ceftizoxime penetration into extravascular spaces with known surface area/volume ratio in vitro and in vivo in rabbits
15. An artificial capillary in vitro kinetic model of antibiotic bactericidal activity
16. A new in vitro model for the assessment of antimicrobial pharmacodynamics: Description and assessment of performance characteristics
17. Differences in antimicrobial effect determined with three in vitro pharmacodynamic models
18. Determination of antibiotic effect in an in vitro pharmacodynamic model: Comparison with an established animal model of infection
19. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models
20. Correction for bacterial loss in in vitro dilution models
21. An in vitro model for the study of antibacterial dosage regimen design
22. A dynamic model for in vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics
23. In vitro models in the study of antibiotic therapy of infections in neutropenic patients
24. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model
25. Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro
26. A pharmacokinetic model for simulating drug concentrations in tissues or fluids and its application to antibiotics
27. Model simulation of a single oral dose of cefuroxime axetil and the related in vitro kill kinetics against four bacterial species
28. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics
29. In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli
30. Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections
31. Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions
32. Ofloxacin: Bactericidal effect in an in vitro pharmacokinetic model
33. Kill kinetics and regrowth pattern of bacteria exposed to antibiotic concentrations simulating those observed in vivo
34. Use of an in vitro kinetic model to study antibiotic combinations
35. Antibacterial kinetics of ampicillin against Escherichia coli under simulated in vivo conditions
36. An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions
37. Bactericidal activity of cefadroxil, cephalexin, and cephradine in an in vitro pharmacokinetics model
38. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels
39. Computer-controlled in vitro simulation of multiple dosing regimens
40. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens
41. Possible approaches to the simulation of antibiotic kinetics and the determination of antibacterial activity in vitro
42. Dual individualization: Antibiotic dosage calculation from the integration of in vitro pharmacodynamics and in vivo pharmacokinetics
43. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model
44. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model
45. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: Prediction of the equivalent AUC/MIC breakpoints and equiefficient doses
46. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
47. Activity of moxifloxacin administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection
48. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection
49. Pharmacodynamics of levofloxacin, ofloxacin and ciprofloxacin alone and in combination with rifampicin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model
50. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
51. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
52. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model
53. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
54. In vivo verification of in vitro model of antibiotic treatment of device-related infection
55. Pharmacodynamics of trovafloxacin ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
56. Variability in antibacterial effect measures used to assess effectiveness of drug regimens in in vitro pharmacodynamic models of infection
57. Inter-and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept
58. Pharmacodynamics of once or twice daily levofloxacin vs vancomycin ± rifampicin against Staphylococcus aureus in an in vitro model with simulated vegetations
59. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations
60. The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear leukocyte chemokinesis
61. An in vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis
62. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model
63. Effect of protein binding on simulated intravascular and extravascular kinetics of cefotaxime in an in vitro model
64. Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection
65. Killing of Pseudomonas aeruginosa during continous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model
66. Bactericidal activity of cefodizime on Enterobacteriaceae in an in vitro model simulating plasma pharmacokinetics in humans
67. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells
68. Activity of imipenem in an in vitro model simulating pharmacokinetic parameters in human blood
69. Application of in vitro models: Development of resistance
70. Two-compartment kinetic model with multiple artificial capillary units
71. Evaluation of the bactericidal activity of β-lactam antibiotics on slowly growing bacteria cultured in the chemostat
72. Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method
73. Artifacts in dilution pharmacokinetic models caused by adherent bacteria
74. In vitro model simulating the form of exposure of bacteria to antimicrobial drugs encountered in infection
75. Comparison of amoxicillin and ampicillin activities in a continuous culture model of human urinary bladder
76. Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters
77. Simultaneous simulation of two different concentration time curves
78. Importance of β-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: Studies with piperacillin-tazobactam and piperacillin-sulbactam
79. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa
80. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
81. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
82. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
83. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
84. In vitro fibrin-clot infection model versus rabbit model of bacterial endocarditis
85. Continuous infusion of β-lactam antibiotics
86. A pilot study studn of the efficacy of constant infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis
87. Differences between bacteria grown in vitro and in vivo
88. Differences between in vitro and in vivo studies
89. Enhancement of leukocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones
90. Adaptation to temperature in bacterial membranes
91. Effects of temperature on antimicrobial susceptibility of bacteria
92. Plasmid-mediated and temperature-regulated surface properties of Yersinia enterocolitica
93. Inoculum effect
94. Virulence of Staphylococcus aureus grown in vitro or in vivo
95. Bacterial adhesion: Modulation by antibiotics which perturb protein synthesis
96. Adherence of Yersinia enterocolitica to mammalian epithelial cell lines
97. Comparisons of Staphylococcus aureus grown in vitro or in vivo
98. Influence of substrate limitation and growth phase on sensitivity to antimicrobial agents
99. Escherichia coli pili as possible mediators of attachment to human urinary tract epithelial cells
100. Variation in the expression of cell wall proteins of Staphylococcus aureus grown on solid and liquid media
101. The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth
102. Tests for bactericidal effects of antimicrobial agents: Technical performance and clinical relevance
103. Epidemiological markers for Pseudomonas aeruginosa
104. The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis
105. Immunochemistry of an acidic antigen isolated from a Staphylococcus aureus
106. Immunochemical study of diverse surface antigens of a Staphyloccus aureus isolate from an osteomyelitis patient and their role in in vitro phagocytosis
107. Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men